Brighter is a Swedish health-tech company that aims to simplify the management of chronic diseases. The company's daily-care solutions facilitate the exchange of real-world treatment data among chronic-disease patients, their loved ones, and healthcare providers. This exchange enhances the quality of life, reduces strain on healthcare systems, and fosters opportunities for data-driven research. Brighter's initial focus is on diabetes, and it has launched Actiste® Diabetes Management as a Service to address this global challenge.
The Actiste device, which utilizes patented technology, enables remote monitoring and data collection on specific biomarkers and medication volumes. Brighter emphasizes the significance of this data-centric approach for smarter care of diabetes and other chronic conditions. Moreover, the company's business model includes out-licensed access to its platform. Continual development of its IP portfolio through both its own applications and in-licensing is an essential aspect of Brighter’s operations, such as the acquisition of micro-needle technology for blood sugar monitoring.
Founded in 2007, Brighter operates within the Biotechnology, Health Care, Information Technology, and Medical Devices industries. The company's most recent investment was a $10.00MPost-IPO Debt investment received on 25 August 2022 from Formue Nord.
